ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

ClinicalTrials.gov ID: NCT06997497

Public ClinicalTrials.gov record NCT06997497. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 12:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)

Study identification

NCT ID
NCT06997497
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
477 participants

Conditions and interventions

Interventions

  • 5-Fluorouracil Drug
  • Bevacizumab Drug
  • Bevacizumab biosimilar Drug
  • Calderasib Drug
  • Cetuximab Biological
  • Leucovorin/levofolinate calcium Drug
  • Oxaliplatin Drug

Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 15, 2025
Primary completion
Mar 27, 2029
Completion
Oct 26, 2030
Last update posted
Apr 27, 2026

2025 – 2030

United States locations

U.S. sites
17
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
Los Angeles Hematology Oncology Medical Group ( Site 0084) Los Angeles California 90017 Recruiting
Florida Cancer Specialists - South ( Site 7002) Fort Myers Florida 33901 Recruiting
Orlando Health Cancer Institute ( Site 0065) Orlando Florida 32806 Recruiting
Florida Cancer Specialists - North ( Site 7001) St. Petersburg Florida 33705 Recruiting
Florida Cancer Specialists - East ( Site 7000) West Palm Beach Florida 33401 Recruiting
University of Iowa ( Site 0074) Iowa City Iowa 52242 Recruiting
University of Kentucky ( Site 0055) Lexington Kentucky 40536 Recruiting
Norton Cancer Institute, Audubon Hospital Campus ( Site 0054) Louisville Kentucky 40217 Recruiting
Greater Baltimore Medical Center ( Site 0068) Baltimore Maryland 21204 Recruiting
Hattiesburg Clinic ( Site 0064) Hattiesburg Mississippi 39401 Recruiting
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 2000) Billings Montana 59102 Recruiting
University Of Nebraska Medical Center ( Site 0078) Omaha Nebraska 68198 Recruiting
Renown Regional Medical Center ( Site 0056) Reno Nevada 89502 Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0060) Hackensack New Jersey 07601 Recruiting
Miami Valley Hospital South ( Site 0075) Centerville Ohio 45459 Recruiting
Community Cancer Trials of Utah ( Site 0086) Ogden Utah 84405 Recruiting
University of Virginia ( Site 0080) Charlottesville Virginia 22908 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 144 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06997497, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 27, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06997497 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →